Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Recognition And Management - NAPLEX

  1. A 59-year-old female (weight 73 kg) with rheumatoid arthritis is taking methotrexate 15 mg by mouth once weekly and calls because she has been taking it daily for the past 5 days due to misunderstanding. Current medications: methotrexate 15 mg (intended weekly), folic acid 1 mg by mouth daily, meloxicam 15 mg by mouth daily. Labs: serum creatinine 1.3 mg/dL, alanine aminotransferase 95 U/L (high), white blood cell count 2.8 x103^3/mcL (low). Allergies: none. Medical history: rheumatoid arthritis. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Hold methotrexate and recommend urgent evaluation due to potential toxicity from daily dosing error This question tests the recognition and management of methotrexate toxicity resulting from a dosing frequency error in a patient with rheumatoid arthritis. The key patient-specific factors include accidental daily administration of methotrexate 15 mg for 5 days instead of weekly, leading to cumulative overdose, as evidenced by elevated alanine aminotransferase (ALT) indicating hepatotoxicity and low white blood cell count suggesting myelosuppression, with mildly elevated serum creatinine potentially exacerbating toxicity. The best recommendation is to hold methotrexate and recommend urgent evaluation due to potential toxicity from the daily dosing error, as this allows for immediate assessment of organ function, possible leucovorin rescue, and supportive care to prevent severe complications like pancytopenia or liver failure. Continuing methotrexate daily and increasing folic acid is incorrect because it perpetuates the erroneous daily dosing, which can worsen toxicity, and higher folic acid alone does not address the overdose. Switching to leflunomide without evaluation or reducing to daily low-dose methotrexate are suboptimal as they ignore the acute toxicity requiring prompt medical intervention and fail to correct the dosing misunderstanding. A key clinical pearl is that methotrexate for rheumatoid arthritis should always be dosed weekly to minimize toxicity risks, and any suspected overdose warrants immediate discontinuation and evaluation. Pharmacists should educate patients on proper dosing schedules and monitor for signs of toxicity through regular lab assessments.
  2. A 68-year-old male (weight 82 kg) presents for follow-up of type 2 diabetes and reports frequent hypoglycemia (sweats, shakiness) over the past 2 weeks after a dose increase. Current medications: insulin glargine 30 units subcutaneously nightly, glipizide immediate-release 10 mg by mouth twice daily (recently increased from 5 mg twice daily), metformin 1000 mg by mouth twice daily, lisinopril 20 mg by mouth daily, atorvastatin 40 mg by mouth nightly. Labs: A1c 6.4%, serum creatinine 1.0 mg/dL, aspartate aminotransferase/alanine aminotransferase within normal limits. Allergies: none. Medical history: type 2 diabetes, hypertension, hyperlipidemia. Which medication change is most appropriate for this patient?
    Answer: Discontinue glipizide and continue insulin glargine and metformin at current doses This question tests the recognition and management of hypoglycemia in type 2 diabetes patients on multiple antidiabetic agents. The key patient-specific factor is the recent glipizide dose increase leading to frequent hypoglycemia symptoms with an A1c of 6.4%, indicating overtreatment. Discontinuing glipizide while continuing insulin glargine and metformin is the best choice because sulfonylureas like glipizide carry a high risk of hypoglycemia, especially in older adults, and removal reduces this risk without compromising control given the low A1c. Decreasing insulin glargine while continuing glipizide is suboptimal as it does not address the primary culprit, and switching to glyburide worsens hypoglycemia risk due to its longer duration. Increasing metformin or continuing glipizide ignores the hypoglycemia and may not adequately mitigate risks. A key clinical pearl is to prioritize de-escalation of high-hypoglycemia-risk agents like sulfonylureas when A1c is below 7% in older patients. Use a framework of assessing A1c, hypoglycemia frequency, and agent risk profiles to guide deprescribing in diabetes management.
  3. A 73-year-old woman (weight 54 kg) is seen in clinic for therapy optimization of hyperlipidemia. Current medications: amlodipine 10 mg once daily and simvastatin 40 mg nightly. Labs: alanine aminotransferase 32 U/L, serum creatinine 0.9 mg/dL; she reports new muscle aches but no dark urine. Allergies: none. Medical history includes hypertension and coronary artery disease. Which medication change is most appropriate for this patient?
    Answer: Switch simvastatin to atorvastatin 40 mg nightly to avoid the simvastatin-amlodipine interaction This question tests recognition of the simvastatin-amlodipine drug interaction and appropriate management. Amlodipine is a moderate CYP3A4 inhibitor that increases simvastatin exposure, with FDA guidance limiting simvastatin to 20 mg daily when used with amlodipine due to increased myopathy risk. The patient's new muscle aches suggest possible statin myopathy from this interaction. Switching to atorvastatin 40 mg avoids the dose limitation while maintaining potent statin therapy for her coronary artery disease. Adding gemfibrozil (choice A) would dangerously increase myopathy risk. Increasing simvastatin to 80 mg (choice B) violates FDA recommendations and worsens toxicity risk. Reducing amlodipine (choice D) may compromise blood pressure control. When patients on amlodipine require statin doses above simvastatin 20 mg daily, switch to atorvastatin or rosuvastatin, which have no dose restrictions with amlodipine.
  4. A 58-year-old female (weight 70 kg) presents with new dry cough and mild lip swelling that started 3 days after starting lisinopril 10 mg by mouth daily for hypertension. Current medications: lisinopril 10 mg daily (started 1 week ago), hydrochlorothiazide 25 mg daily, metformin 500 mg twice daily. Labs: serum creatinine 0.9 mg/dL, potassium 4.6 mEq/L, alanine aminotransferase within normal limits. Allergies: penicillin (rash). Medical history: hypertension, type 2 diabetes. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Stop lisinopril and recommend urgent evaluation due to possible angioedema This question tests the recognition and management of angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema. The key patient-specific factor is the new onset of dry cough and mild lip swelling shortly after starting lisinopril, suggestive of angioedema. Stopping lisinopril and recommending urgent evaluation is the best choice because ACEI-induced angioedema can progress to life-threatening airway compromise and requires immediate discontinuation. Continuing lisinopril with diphenhydramine or reducing the dose risks escalation of symptoms, while switching to another ACEI like enalapril is inappropriate due to class-wide risk. A clinical pearl is that ACEI angioedema often presents with facial or lip swelling and can occur at any time during therapy, though commonly early on. Employ a decision framework of assessing symptom timing relative to drug initiation and prioritizing discontinuation for suspected serious adverse reactions like angioedema.
  5. A 71-year-old male (weight 76 kg) is taking digoxin 0.25 mg by mouth daily for atrial fibrillation rate control and reports nausea, loss of appetite, and yellow-tinged vision. Current medications: digoxin 0.25 mg daily, furosemide 40 mg daily, metoprolol succinate 50 mg daily, potassium chloride 20 mEq daily. Labs: serum creatinine 1.8 mg/dL, potassium 3.1 mEq/L (low). Allergies: none. Medical history: atrial fibrillation, heart failure with reduced ejection fraction, chronic kidney disease. Which monitoring parameter should be prioritized?
    Answer: Serum digoxin concentration and electrolytes (especially potassium) This question tests monitoring for digoxin toxicity in patients with heart failure and atrial fibrillation. The key patient-specific factor is symptoms of nausea, anorexia, and visual changes alongside hypokalemia and elevated creatinine, which increase digoxin toxicity risk. Prioritizing serum digoxin concentration and electrolytes, especially potassium, is essential as hypokalemia potentiates digoxin toxicity and levels guide dosing adjustments. Hemoglobin A1c, INR, or amylase/lipase are irrelevant without diabetes, anticoagulation, or pancreatitis concerns. A clinical pearl is that digoxin toxicity often manifests with gastrointestinal and visual symptoms, exacerbated by renal impairment or low potassium. Apply a framework of assessing symptoms, electrolytes, and renal function before obtaining digoxin levels to manage potential toxicity effectively.
  6. A 52-year-old male (weight 88 kg) is newly diagnosed with hypertension and is prescribed hydrochlorothiazide 25 mg by mouth daily. Current medications: none. Labs: serum creatinine 1.0 mg/dL, sodium 140 mEq/L, potassium 4.2 mEq/L, fasting glucose 102 mg/dL. Allergies: sulfonamide antibiotic (trimethoprim-sulfamethoxazole) caused hives and facial swelling. Medical history: none significant. What is the most important counseling point for this treatment?
    Answer: Monitor for dizziness and dehydration, and have electrolytes checked after starting therapy This question tests counseling on diuretic therapy in patients with sulfonamide allergies. The key patient-specific factor is the history of hives and facial swelling to trimethoprim-sulfamethoxazole, but cross-reactivity with non-antibiotic sulfonamides like hydrochlorothiazide is rare and not an absolute contraindication. Monitoring for dizziness, dehydration, and electrolytes after starting is the best counseling point as thiazides can cause electrolyte imbalances and orthostasis, which are common adverse effects requiring vigilance. Stopping for muscle pain confuses it with statin effects, avoiding all thiazides overstates the allergy risk, and taking with grapefruit is irrelevant and potentially harmful. A clinical pearl is that sulfonamide antibiotic allergies do not preclude thiazide use unless severe, but baseline and follow-up electrolyte checks are essential. Employ a framework of assessing allergy severity and educating on common side effects like hypokalemia while debunking myths about cross-reactivity.
  7. A 48-year-old female (weight 69 kg) with gastroesophageal reflux disease reports persistent heartburn despite omeprazole 20 mg by mouth daily taken 'whenever I remember,' usually with dinner. Current medications: omeprazole 20 mg daily (inconsistent), calcium carbonate chewable tablets as needed. Labs: serum creatinine 0.8 mg/dL, liver function tests within normal limits. Allergies: none. Medical history: GERD. What is the best intervention for this patient's medication adherence issue?
    Answer: Counsel to take omeprazole 30–60 minutes before the first meal daily and set a consistent reminder This question tests interventions for suboptimal proton pump inhibitor (PPI) use in GERD. The key patient-specific factor is inconsistent omeprazole timing, usually with dinner, reducing efficacy as PPIs work best pre-meal to inhibit acid pumps. Counseling on 30-60 minutes before the first meal with reminders is best to optimize acid suppression and adherence. Taking only after symptoms, switching to ranitidine, or doubling dose without timing correction is less effective. A clinical pearl is that PPIs require consistent pre-breakfast dosing for maximal benefit in GERD. Apply a decision framework of assessing administration habits and educating on pharmacokinetics to improve therapeutic outcomes.
  8. A 57-year-old male (weight 92 kg) with gout is started on allopurinol 300 mg by mouth daily and returns 2 weeks later with fever and a widespread rash. Current medications: allopurinol 300 mg daily (new), hydrochlorothiazide 25 mg daily, ibuprofen 400 mg as needed. Labs: alanine aminotransferase 110 U/L (high), serum creatinine 1.4 mg/dL. Allergies: none. Medical history: gout, hypertension. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Stop allopurinol and recommend urgent evaluation due to possible severe hypersensitivity reaction This question tests the identification of allopurinol hypersensitivity syndrome. The key patient-specific factor is fever, widespread rash, and elevated liver enzymes shortly after starting allopurinol, indicative of a severe reaction like DRESS syndrome. Stopping allopurinol and recommending urgent evaluation is best as hypersensitivity can progress to multi-organ involvement requiring immediate cessation. Adding hydrocortisone, increasing dose, or switching to febuxostat without evaluation delays care and risks continuation of harm. A clinical pearl is that allopurinol hypersensitivity often occurs within weeks and is more common in those with renal impairment or on thiazides. Use a framework of correlating symptom onset with drug initiation and prioritizing discontinuation for suspected severe cutaneous reactions.
  9. A 29-year-old woman (weight 66 kg) is picking up a new prescription for sertraline 50 mg once daily for major depressive disorder. Current medications include sumatriptan 50 mg as needed for migraine (uses 1–2 doses per week) and ethinyl estradiol/levonorgestrel 1 tablet daily. Labs: alanine aminotransferase 20 U/L, serum creatinine 0.7 mg/dL. Allergies: none. What is the most important counseling point for this treatment?
    Answer: Seek medical attention if you develop agitation, tremor, sweating, or diarrhea when using sertraline with sumatriptan due to possible serotonin syndrome This question tests recognition of serotonin syndrome risk with concurrent serotonergic medications. The patient is starting sertraline (SSRI) while taking sumatriptan (5-HT1 agonist), creating potential for serotonin syndrome, especially during migraine attacks when both are used together. Warning signs include agitation, tremor, sweating, and diarrhea, which require immediate medical attention. Taking sertraline as needed (choice A) is incorrect as SSRIs require daily dosing for efficacy. Tyramine restriction (choice B) applies to MAOIs, not SSRIs. SSRIs don't affect oral contraceptive efficacy (choice D). When patients use multiple serotonergic agents, educate about serotonin syndrome symptoms and emphasize seeking immediate care if they develop, particularly when using triptans for breakthrough migraines.
  10. A 64-year-old man (weight 76 kg) with gout calls the pharmacy about severe diarrhea and abdominal cramping that began after a recent medication change. He started colchicine 0.6 mg twice daily yesterday for an acute gout flare and is also taking clarithromycin 500 mg twice daily for pneumonia started 3 days ago. Current medications: colchicine 0.6 mg twice daily, clarithromycin 500 mg twice daily, allopurinol 300 mg once daily, and losartan 50 mg once daily. Labs: serum creatinine 1.2 mg/dL (estimated creatinine clearance 55 mL/min), alanine aminotransferase 25 U/L. Allergies: none. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Hold colchicine and contact the prescriber due to a major interaction with clarithromycin that increases colchicine toxicity risk This question tests recognition of a major drug interaction causing colchicine toxicity. Clarithromycin is a potent CYP3A4 and P-glycoprotein inhibitor that dramatically increases colchicine levels, causing severe gastrointestinal toxicity (diarrhea, cramping) and potentially life-threatening complications. The patient's reduced creatinine clearance (55 mL/min) further increases risk. Immediate discontinuation of colchicine and prescriber notification is essential. Continuing both drugs (choice A) risks serious toxicity including rhabdomyolysis and multi-organ failure. Increasing colchicine (choice B) would worsen toxicity. Independently switching antibiotics (choice D) exceeds pharmacist scope and may not adequately treat the pneumonia. When patients require colchicine for acute gout flares while on strong CYP3A4 inhibitors like clarithromycin, alternative gout treatments (NSAIDs, corticosteroids) should be used, or wait until antibiotic course completion.
  11. A 68-year-old man (weight 82 kg) is admitted for dizziness and near-syncope. During medication reconciliation, he reports taking metoprolol succinate 100 mg once daily, diltiazem extended-release 240 mg once daily, lisinopril 20 mg once daily, and atorvastatin 40 mg nightly; heart rate is 44 beats/min and blood pressure is 98/56 mm Hg. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 28 U/L. He has no drug allergies and a history of hypertension and stable angina. Which medication change is most appropriate for this patient?
    Answer: Discontinue diltiazem and continue metoprolol succinate 100 mg once daily This question tests recognition of symptomatic bradycardia caused by concurrent use of two negative chronotropic agents. The patient's heart rate of 44 bpm with hypotension and symptoms of dizziness/near-syncope indicates excessive AV nodal blockade from the combination of metoprolol (beta-blocker) and diltiazem (non-dihydropyridine calcium channel blocker). Discontinuing diltiazem and continuing metoprolol is the best choice because it eliminates the drug interaction while maintaining beta-blockade for the patient's stable angina. Continuing both agents with a diuretic (choice A) would worsen hypotension without addressing the bradycardia. Switching to carvedilol while continuing diltiazem (choice C) maintains the problematic combination. Reducing metoprolol while continuing diltiazem (choice D) may not adequately resolve the bradycardia. When patients develop symptomatic bradycardia from concurrent negative chronotropes, discontinue one agent rather than reducing doses of both.
  12. A 63-year-old male (weight 95 kg) with chronic kidney disease presents for diabetes management. Current medications: metformin 1000 mg by mouth twice daily, empagliflozin 10 mg by mouth daily, amlodipine 10 mg by mouth daily. Labs: A1c 8.2%, serum creatinine 2.3 mg/dL with estimated glomerular filtration rate (eGFR) 26 mL/min/1.73 m2^2, alanine aminotransferase within normal limits. Allergies: none. Medical history: type 2 diabetes, CKD stage 4, hypertension. Which therapy adjustment is necessary based on the patient's lab results?
    Answer: Discontinue metformin due to low eGFR and reassess glycemic regimen This question tests the recognition of metformin contraindications in patients with impaired renal function. The key patient-specific factor is the eGFR of 26 mL/min/1.73 m², which is below the threshold for safe metformin use due to lactic acidosis risk. Discontinuing metformin and reassessing the glycemic regimen is the best choice as guidelines contraindicate metformin when eGFR is below 30 mL/min/1.73 m². Continuing or increasing metformin, adding glyburide, or switching to extended-release ignores the renal impairment and heightens adverse event risk. A clinical pearl is that metformin accumulation in CKD can lead to rare but serious lactic acidosis, necessitating prompt discontinuation. Apply a decision framework of routinely checking eGFR before and during metformin therapy, with discontinuation if below 30 mL/min/1.73 m² and alternative agents like SGLT2 inhibitors if appropriate.
  13. A 62-year-old female (weight 66 kg) is on chronic prednisone 10 mg by mouth daily for polymyalgia rheumatica and is newly prescribed alendronate 70 mg by mouth once weekly for osteoporosis prevention. Current medications: prednisone 10 mg daily, alendronate 70 mg weekly (new), omeprazole 20 mg daily. Labs: serum creatinine 0.9 mg/dL, calcium 9.2 mg/dL. Allergies: none. Medical history: polymyalgia rheumatica, gastroesophageal reflux disease. What is the most important counseling point for this treatment?
    Answer: Take alendronate with a full glass of water upon waking and remain upright for at least 30 minutes This question tests proper administration counseling for bisphosphonates to minimize esophageal irritation. The key patient-specific factor is new alendronate prescription in a patient on chronic prednisone with GERD, heightening esophagitis risk if not taken correctly. Counseling to take with a full glass of water upon waking and remain upright for 30 minutes is most important to ensure proper transit and reduce irritation. Taking at bedtime with food, crushing, or with calcium impairs absorption and increases adverse effects. A clinical pearl is that bisphosphonates require fasting and upright posture to prevent esophageal ulceration, especially in GERD patients. Employ a framework of emphasizing administration techniques and monitoring for dysphagia to optimize safety in osteoporosis therapy.
  14. A 33-year-old male (weight 75 kg) is prescribed amoxicillin 500 mg by mouth three times daily for sinusitis and develops hives and itching after the second dose. Current medications: amoxicillin 500 mg three times daily (new), cetirizine 10 mg daily as needed. Labs: serum creatinine 0.8 mg/dL. Allergies: none previously documented. Medical history: seasonal allergies. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Stop amoxicillin, recommend contacting the prescriber for an alternative, and document a probable penicillin allergy This question tests the management of probable penicillin allergy during antibiotic therapy. The key patient-specific factor is hives and itching after the second amoxicillin dose, suggesting an IgE-mediated reaction requiring avoidance. Stopping amoxicillin, contacting the prescriber for an alternative, and documenting the allergy is best to prevent escalation to anaphylaxis. Continuing with diphenhydramine, switching to ampicillin, or increasing dose risks severe reactions. A clinical pearl is that beta-lactam allergies should be clarified by reaction type, with immediate hypersensitivity warranting class avoidance. Use a framework of evaluating reaction timing and symptoms to guide discontinuation and allergy documentation for future prescribing.
  15. A 55-year-old woman (weight 74 kg) presents to the pharmacy with diffuse hives and lip swelling that started 2 days after starting trimethoprim-sulfamethoxazole 1 double-strength tablet twice daily for a urinary tract infection. Current medications include lisinopril 10 mg once daily and metformin 1000 mg twice daily. Labs from yesterday: serum creatinine 0.9 mg/dL, aspartate aminotransferase 22 U/L; no prior history of urticaria. Allergy history: none documented. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Stop trimethoprim-sulfamethoxazole and refer for urgent evaluation due to possible angioedema; update allergy to sulfonamide antibiotic This question tests recognition and management of a severe hypersensitivity reaction to trimethoprim-sulfamethoxazole. The patient presents with diffuse hives and lip swelling (angioedema) within 2 days of starting the antibiotic, which is characteristic of a Type I hypersensitivity reaction. Immediate discontinuation and urgent referral is the best choice because angioedema can progress to life-threatening airway obstruction. Adding diphenhydramine while continuing the offending drug (choice B) is dangerous and inappropriate. Switching antibiotics without prescriber contact (choice C) exceeds pharmacist scope and doesn't address the acute reaction. The timing and presentation are inconsistent with ACE inhibitor cough (choice D), which is a dry cough without urticaria or angioedema. When patients develop angioedema or severe urticaria from any medication, immediate discontinuation and urgent medical evaluation are mandatory, with documentation of the allergy to prevent future exposure.
  16. A 58-year-old man (weight 102 kg) with COPD presents to the pharmacy stating he "doesn't feel his inhalers work" and admits he often skips doses because he is confused by his regimen. Current medications: tiotropium 18 mcg inhaled once daily, fluticasone/salmeterol 250/50 mcg inhaled 1 puff twice daily, albuterol HFA 2 puffs every 4–6 hours as needed, and omeprazole 20 mg once daily. He reports 2 COPD exacerbations requiring oral prednisone in the last year. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 26 U/L. No known drug allergies. What is the best intervention for this patient's medication adherence issue?
    Answer: Provide in-person inhaler technique assessment and create a simplified written schedule distinguishing maintenance vs rescue inhalers This question tests medication adherence interventions for complex inhaler regimens in COPD. The patient's confusion about his inhaler regimen and admission of skipping doses indicates poor inhaler technique and lack of understanding about maintenance versus rescue therapy. In-person technique assessment with a simplified written schedule is the most effective intervention to improve adherence and outcomes. Discontinuing tiotropium (choice A) would worsen COPD control by removing long-acting bronchodilation. Switching to oral prednisone (choice C) for maintenance is inappropriate due to systemic side effects. Scheduled albuterol (choice D) is not recommended and doesn't address the adherence issue. For patients struggling with multiple inhalers, hands-on technique training combined with clear written instructions distinguishing daily maintenance from as-needed rescue medications significantly improves adherence and disease control.
  17. A 73-year-old male (weight 78 kg) with chronic pain and insomnia is taking multiple sedating medications and reports two falls in the last month. Current medications: zolpidem 10 mg by mouth nightly, diphenhydramine 50 mg by mouth nightly as needed, oxycodone 5 mg by mouth every 6 hours as needed, cyclobenzaprine 10 mg by mouth three times daily as needed, sertraline 50 mg by mouth daily. Labs: serum creatinine 1.2 mg/dL, alanine aminotransferase within normal limits. Allergies: none. Medical history: osteoarthritis, insomnia, depression. Which medication change is most appropriate for this patient?
    Answer: Recommend deprescribing high-risk sedatives (e.g., diphenhydramine) and reassessing zolpidem dose due to fall risk This question tests deprescribing in older adults with polypharmacy and fall risk. The key patient-specific factor is multiple sedatives (zolpidem, diphenhydramine, etc.) contributing to falls via CNS depression. Recommending deprescribing high-risk sedatives and reassessing zolpidem is best to minimize fall risk while addressing insomnia. Adding lorazepam, increasing zolpidem, or switching to hydroxyzine increases sedation burden. A clinical pearl is that Beers criteria highlight sedatives like non-benzodiazepine hypnotics and antihistamines as high-risk for falls in elderly. Use a framework of evaluating medication lists for CNS-active agents and prioritizing gradual deprescribing to enhance safety.
  18. A 66-year-old female (weight 68 kg) on warfarin for atrial fibrillation calls the pharmacy after starting trimethoprim-sulfamethoxazole yesterday for a urinary tract infection. Current medications: warfarin 4 mg by mouth daily, amiodarone 200 mg by mouth daily, levothyroxine 75 mcg by mouth daily. Labs: INR 2.4 yesterday (goal 2–3), serum creatinine 1.0 mg/dL. Allergies: none. Medical history: atrial fibrillation, hypothyroidism. Which monitoring parameter should be prioritized?
    Answer: INR within 2–3 days after starting the antibiotic and again after completion This question tests monitoring for warfarin-antibiotic interactions. The key patient-specific factor is the initiation of trimethoprim-sulfamethoxazole, which can potentiate warfarin's anticoagulant effect via CYP2C9 inhibition and vitamin K disruption. Prioritizing INR within 2-3 days and after completion is essential to detect and adjust for supratherapeutic levels promptly. Serum magnesium, A1c, or urine ketones are irrelevant without related indications. A clinical pearl is that antibiotics like trimethoprim-sulfamethoxazole commonly increase INR in warfarin patients, requiring close monitoring. Use a framework of identifying high-risk interactors and scheduling INR checks based on interaction onset and duration for safe anticoagulation management.
  19. A 50-year-old male (weight 86 kg) reports severe muscle pain and dark urine 2 weeks after starting clarithromycin for bronchitis. Current medications: simvastatin 40 mg by mouth nightly, clarithromycin 500 mg by mouth twice daily (day 10 of 10), amlodipine 5 mg by mouth daily. Labs: creatine kinase 3200 U/L (high), serum creatinine 1.6 mg/dL (baseline 1.0), alanine aminotransferase 55 U/L (high). Allergies: none. Medical history: hyperlipidemia, hypertension. What is the pharmacist's best recommendation for managing this adverse drug reaction?
    Answer: Stop simvastatin and advise immediate medical evaluation for possible rhabdomyolysis This question tests the recognition and management of statin-macrolide interactions leading to rhabdomyolysis. The key patient-specific factor is severe muscle pain, dark urine, elevated CK, and renal impairment after clarithromycin initiation with simvastatin, due to CYP3A4 inhibition increasing statin levels. Stopping simvastatin and advising immediate evaluation is best to prevent further muscle damage and acute kidney injury. Continuing or increasing simvastatin, or switching to lovastatin, exacerbates the interaction risk. A clinical pearl is that clarithromycin strongly inhibits simvastatin metabolism, necessitating hold or switch to safer statins like pravastatin. Employ a framework of assessing symptom timing with interactors and monitoring CK for prompt intervention in suspected rhabdomyolysis.
  20. A 70-year-old male (weight 84 kg) with heart failure is taking spironolactone 25 mg by mouth daily and lisinopril 20 mg by mouth daily. He now has weakness and palpitations. Labs: potassium 6.1 mEq/L (high), serum creatinine 2.0 mg/dL, estimated glomerular filtration rate 32 mL/min/1.73 m2^2. Current medications also include carvedilol 12.5 mg twice daily and furosemide 20 mg daily. Allergies: none. Medical history: heart failure with reduced ejection fraction, chronic kidney disease. Which therapy adjustment is necessary based on the patient's lab results?
    Answer: Hold spironolactone and urgently address hyperkalemia while assessing contributing medications This question tests the management of hyperkalemia in heart failure patients on renin-angiotensin-aldosterone system inhibitors. The key patient-specific factor is potassium of 6.1 mEq/L with symptoms of weakness and palpitations, exacerbated by combined spironolactone and lisinopril in renal impairment. Holding spironolactone and urgently addressing hyperkalemia while assessing contributors is necessary to prevent arrhythmias. Increasing spironolactone, adding potassium, or switching to losartan worsens hyperkalemia risk. A clinical pearl is that aldosterone antagonists like spironolactone require close potassium monitoring, especially with ACEIs and in CKD. Use a decision framework of evaluating potassium levels, renal function, and symptoms to guide temporary holds and corrections in hyperkalemia.

Start this quiz